Prevalence of cardiovascular risk factors in men with stable coronary heart disease in France and Spain.

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  Eric Boerwinkle,et al.  The Atherosclerosis Risk in Communities (ARIC) Study , 2011 .

[3]  D. Arveiler,et al.  Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. , 2009, Archives of cardiovascular diseases.

[4]  K. Kotseva,et al.  Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.

[5]  M. J. Medrano,et al.  Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española , 2007 .

[6]  R. Elosua,et al.  Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[8]  E. Braunwald,et al.  Recent trials of lipid lowering , 2007, International journal of clinical practice.

[9]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[10]  P. Steg,et al.  Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.

[11]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[12]  J. Hippisley-Cox,et al.  Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis , 2005, BMJ : British Medical Journal.

[13]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[14]  J. Ferrières,et al.  Comparison of cardiovascular risk factors and drug use in 14544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[15]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[16]  J. Ferrières.  The French paradox: lessons for other countries , 2003, Heart.

[17]  A. Dyer,et al.  Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.

[18]  P. Whincup,et al.  Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. , 2003, European heart journal.

[19]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[20]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[21]  R. Beaglehole,et al.  The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? , 2002, International journal of epidemiology.

[22]  J. Ferrières,et al.  Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey , 2002, Heart.

[23]  J. Cosín,et al.  Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II , 2002 .

[24]  M. de Oya,et al.  [New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study]. , 2002, Revista espanola de cardiologia.

[25]  D. Arveiler,et al.  Types of alcoholic beverages and blood lipids in a French population , 2002, Journal of epidemiology and community health.

[26]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[27]  J. Willerson,et al.  Prospects for cardiovascular research. , 2001, JAMA.

[28]  A. Dyer,et al.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.

[29]  J. Marrugat,et al.  High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. , 1998, Journal of epidemiology and community health.

[30]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[31]  C. Hennekens.  Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. , 1998, Circulation.

[32]  D. Wood.  European Action on Secondary Prevention by Intervention to Reduce Events , 1998 .

[33]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[34]  A. Folsom,et al.  A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 1997, Diabetes Care.

[35]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[36]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[37]  M. Medrano,et al.  [Coronary disease risk attributable to cardiovascular risk factors in the Spanish population]. , 2007, Revista espanola de cardiologia.

[38]  D. Arveiler,et al.  Change in cardiovascular risk factors in France, 1985–1997 , 2004, European Journal of Epidemiology.

[39]  [Therapeutic management of patients with dyslipidemia. Text of recommendations. September 2000]. , 2001, Journal des maladies vasculaires.

[40]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.